FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
ECHELON‐1 study is a randomized open‐labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow‐up of 24.6 months, it has met its primary endpoint the reducti...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2019-09, Vol.103 (3), p.145-151 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 151 |
|---|---|
| container_issue | 3 |
| container_start_page | 145 |
| container_title | European journal of haematology |
| container_volume | 103 |
| creator | Milunović, Vibor Mišura Jakobac, Karla Kursar, Marin Mandac Rogulj, Inga Ostojić Kolonić, Slobodanka |
| description | ECHELON‐1 study is a randomized open‐labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow‐up of 24.6 months, it has met its primary endpoint the reduction of modified progression‐free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in‐depth insight of pros and cons of this novel, promising but ultimately controversial regimen. |
| doi_str_mv | 10.1111/ejh.13269 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2242816333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2277306748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3889-1b9f84e37207356fba96077c5706c80e721f3bc3dc1e1def26c9d7a5d26048c73</originalsourceid><addsrcrecordid>eNp1kTFPwzAQhS0EglIY-APIEgMwhJ7t1E5YUAUtBYFYYI4c26EtSRzspNB_j6HAgMQt57M_PZ3fQ-iAwBkJNTCL2RlhlKcbqEc4QAQc0k3UgxRoFMcx2UG73i8AgKZEbKMdRgjnwKCHFpOr0bHHstZ4fP91ahpnl7LEtsC5M3Xbvc8rmeOl0bad17iwDku9lLUyGk-tfn4Jl-Wqama2kud4VNt2ZhxuSrkKLbyFEbf2rb7YQ1uFLL3Z_-599DQZP15Oo7uH65vL0V2kWJKkEcnTIokNExQEG_IilykHIdRQAFcJGEFJwXLFtCKGaFNQrlIt5FBTDnGiBOujk7Vu-MhrZ3ybVXOvTFnK2tjOZ5TGNCGcheqjoz_ownauDtsFSggGXMRJoE7XlHLWe2eKrHHBE7fKCGSfAWQhgOwrgMAefit2eWX0L_njeAAGa-BtXprV_0rZ-Ha6lvwAbSWNYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2277306748</pqid></control><display><type>article</type><title>FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Milunović, Vibor ; Mišura Jakobac, Karla ; Kursar, Marin ; Mandac Rogulj, Inga ; Ostojić Kolonić, Slobodanka</creator><creatorcontrib>Milunović, Vibor ; Mišura Jakobac, Karla ; Kursar, Marin ; Mandac Rogulj, Inga ; Ostojić Kolonić, Slobodanka</creatorcontrib><description>ECHELON‐1 study is a randomized open‐labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow‐up of 24.6 months, it has met its primary endpoint the reduction of modified progression‐free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in‐depth insight of pros and cons of this novel, promising but ultimately controversial regimen.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.13269</identifier><identifier>PMID: 31166030</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Agents, Immunological - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; brentuximab vedotin ; Brentuximab Vedotin - administration & dosage ; Brentuximab Vedotin - adverse effects ; Brentuximab Vedotin - therapeutic use ; Chemotherapy ; Clinical Trials, Phase III as Topic ; Drug Approval ; Europe ; Hodgkin Disease - diagnosis ; Hodgkin Disease - drug therapy ; Hodgkin Disease - etiology ; Hodgkin lymphoma ; Hodgkin's lymphoma ; Humans ; Immunotherapy ; induction chemotherapy ; Lymphoma ; Monoclonal antibodies ; Multicenter Studies as Topic ; Neoplasm Metastasis ; Neoplasm Staging ; Randomized Controlled Trials as Topic ; Targeted cancer therapy ; Treatment Outcome ; United States ; United States Food and Drug Administration</subject><ispartof>European journal of haematology, 2019-09, Vol.103 (3), p.145-151</ispartof><rights>2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3889-1b9f84e37207356fba96077c5706c80e721f3bc3dc1e1def26c9d7a5d26048c73</citedby><cites>FETCH-LOGICAL-c3889-1b9f84e37207356fba96077c5706c80e721f3bc3dc1e1def26c9d7a5d26048c73</cites><orcidid>0000-0002-6487-3623</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.13269$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.13269$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31166030$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Milunović, Vibor</creatorcontrib><creatorcontrib>Mišura Jakobac, Karla</creatorcontrib><creatorcontrib>Kursar, Marin</creatorcontrib><creatorcontrib>Mandac Rogulj, Inga</creatorcontrib><creatorcontrib>Ostojić Kolonić, Slobodanka</creatorcontrib><title>FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>ECHELON‐1 study is a randomized open‐labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow‐up of 24.6 months, it has met its primary endpoint the reduction of modified progression‐free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in‐depth insight of pros and cons of this novel, promising but ultimately controversial regimen.</description><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>brentuximab vedotin</subject><subject>Brentuximab Vedotin - administration & dosage</subject><subject>Brentuximab Vedotin - adverse effects</subject><subject>Brentuximab Vedotin - therapeutic use</subject><subject>Chemotherapy</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Drug Approval</subject><subject>Europe</subject><subject>Hodgkin Disease - diagnosis</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - etiology</subject><subject>Hodgkin lymphoma</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>induction chemotherapy</subject><subject>Lymphoma</subject><subject>Monoclonal antibodies</subject><subject>Multicenter Studies as Topic</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kTFPwzAQhS0EglIY-APIEgMwhJ7t1E5YUAUtBYFYYI4c26EtSRzspNB_j6HAgMQt57M_PZ3fQ-iAwBkJNTCL2RlhlKcbqEc4QAQc0k3UgxRoFMcx2UG73i8AgKZEbKMdRgjnwKCHFpOr0bHHstZ4fP91ahpnl7LEtsC5M3Xbvc8rmeOl0bad17iwDku9lLUyGk-tfn4Jl-Wqama2kud4VNt2ZhxuSrkKLbyFEbf2rb7YQ1uFLL3Z_-599DQZP15Oo7uH65vL0V2kWJKkEcnTIokNExQEG_IilykHIdRQAFcJGEFJwXLFtCKGaFNQrlIt5FBTDnGiBOujk7Vu-MhrZ3ybVXOvTFnK2tjOZ5TGNCGcheqjoz_ownauDtsFSggGXMRJoE7XlHLWe2eKrHHBE7fKCGSfAWQhgOwrgMAefit2eWX0L_njeAAGa-BtXprV_0rZ-Ha6lvwAbSWNYw</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Milunović, Vibor</creator><creator>Mišura Jakobac, Karla</creator><creator>Kursar, Marin</creator><creator>Mandac Rogulj, Inga</creator><creator>Ostojić Kolonić, Slobodanka</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6487-3623</orcidid></search><sort><creationdate>201909</creationdate><title>FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?</title><author>Milunović, Vibor ; Mišura Jakobac, Karla ; Kursar, Marin ; Mandac Rogulj, Inga ; Ostojić Kolonić, Slobodanka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3889-1b9f84e37207356fba96077c5706c80e721f3bc3dc1e1def26c9d7a5d26048c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>brentuximab vedotin</topic><topic>Brentuximab Vedotin - administration & dosage</topic><topic>Brentuximab Vedotin - adverse effects</topic><topic>Brentuximab Vedotin - therapeutic use</topic><topic>Chemotherapy</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Drug Approval</topic><topic>Europe</topic><topic>Hodgkin Disease - diagnosis</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - etiology</topic><topic>Hodgkin lymphoma</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>induction chemotherapy</topic><topic>Lymphoma</topic><topic>Monoclonal antibodies</topic><topic>Multicenter Studies as Topic</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Milunović, Vibor</creatorcontrib><creatorcontrib>Mišura Jakobac, Karla</creatorcontrib><creatorcontrib>Kursar, Marin</creatorcontrib><creatorcontrib>Mandac Rogulj, Inga</creatorcontrib><creatorcontrib>Ostojić Kolonić, Slobodanka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Milunović, Vibor</au><au>Mišura Jakobac, Karla</au><au>Kursar, Marin</au><au>Mandac Rogulj, Inga</au><au>Ostojić Kolonić, Slobodanka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2019-09</date><risdate>2019</risdate><volume>103</volume><issue>3</issue><spage>145</spage><epage>151</epage><pages>145-151</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>ECHELON‐1 study is a randomized open‐labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow‐up of 24.6 months, it has met its primary endpoint the reduction of modified progression‐free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in‐depth insight of pros and cons of this novel, promising but ultimately controversial regimen.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31166030</pmid><doi>10.1111/ejh.13269</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6487-3623</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2019-09, Vol.103 (3), p.145-151 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2242816333 |
| source | MEDLINE; Wiley Online Library |
| subjects | Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use brentuximab vedotin Brentuximab Vedotin - administration & dosage Brentuximab Vedotin - adverse effects Brentuximab Vedotin - therapeutic use Chemotherapy Clinical Trials, Phase III as Topic Drug Approval Europe Hodgkin Disease - diagnosis Hodgkin Disease - drug therapy Hodgkin Disease - etiology Hodgkin lymphoma Hodgkin's lymphoma Humans Immunotherapy induction chemotherapy Lymphoma Monoclonal antibodies Multicenter Studies as Topic Neoplasm Metastasis Neoplasm Staging Randomized Controlled Trials as Topic Targeted cancer therapy Treatment Outcome United States United States Food and Drug Administration |
| title | FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A54%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FDA's%20and%20EMA's%20approval%20of%20brentuximab%20vedotin%20for%20advanced%20Hodgkin%20lymphoma:%20Another%20player%20in%20the%20town?&rft.jtitle=European%20journal%20of%20haematology&rft.au=Milunovi%C4%87,%20Vibor&rft.date=2019-09&rft.volume=103&rft.issue=3&rft.spage=145&rft.epage=151&rft.pages=145-151&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.13269&rft_dat=%3Cproquest_cross%3E2277306748%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2277306748&rft_id=info:pmid/31166030&rfr_iscdi=true |